A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Trial Profile

A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Epacadostat (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Aug 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top